首页> 外文期刊>Journal of Ophthalmic Inflammation and Infection >Dexamethasone intravitreal implants in the management of tubercular multifocal serpiginoid choroiditis
【24h】

Dexamethasone intravitreal implants in the management of tubercular multifocal serpiginoid choroiditis

机译:地塞米松玻璃体内植入物治疗结核性多灶性类鼻咽样脉络膜炎

获取原文
       

摘要

Continuous progression of lesions despite an adequate treatment has been described in tubercular multifocal serpiginoid choroiditis. Reported treatments for this paradoxical response include systemic steroids, immunosuppressive drugs, and intravitreal methotrexate. We describe the use of dexamethasone intravitreal implants in a patient presenting with this condition. A 46-year-old woman sought medical attention for scotomas in her left eye. Tests suggested multifocal serpiginoid choroiditis associated with latent tuberculosis infection, and hence, she was started on anti-tuberculosis drugs in combination with corticosteroids. Given that lesions progressed despite this treatment, we began treatment with dexamethasone intravitreal implants. After injection of the second implant, we succeeded in inactivating the inflammatory process. Dexamethasone intravitreal implants may be a suitable alternative to systemic steroids or immunosuppressive therapy in the management of continuous progression of lesions in tubercular multifocal serpiginoid choroiditis.
机译:尽管在结核性多灶性类螺旋体脉络膜炎中进行了充分的治疗,但病灶仍在持续发展。据报道,这种反常反应的治疗方法包括全身性类固醇,免疫抑制剂和玻璃体内甲氨蝶呤。我们描述了在患有这种情况的患者中使用地塞米松玻璃体内植入物。一名46岁的女性因左眼患有肉瘤而寻求医疗救治。测试表明与局灶性肺结核感染有关的多灶性类鼻咽样脉络膜炎,因此,她开始接受抗结核药物与糖皮质激素的联合治疗。鉴于尽管进行了这种治疗,病变仍在发展,所以我们开始使用地塞米松玻璃体内植入物进行治疗。注射第二个植入物后,我们成功地使炎症过程失活。地塞米松玻璃体内植入物在治疗结核性多灶性类鼻咽样脉络膜炎的病灶连续进展中可能是全身性类固醇或免疫抑制疗法的合适替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号